Company news
Entera Bio Ltd. (NASDAQ:ENTX) news
Every Entera Bio Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Correction: Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Init...
August 18, 2026
Entera Announces Second Quarter 2026 Financial Results and Business Updates
August 7, 2026
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fr...
August 4, 2026
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 31, 2026
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
July 29, 2026
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
July 27, 2026
America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX)
July 8, 2026
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Developm...
June 22, 2026
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity a...
June 16, 2026
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1...
June 15, 2026
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation...
May 28, 2026
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
May 8, 2026
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
April 14, 2026
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
April 2, 2026
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
March 27, 2026
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
March 4, 2026
Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board
February 27, 2026
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
February 26, 2026
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
February 11, 2026
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
February 9, 2026
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
February 4, 2026
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
January 21, 2026
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporo...
December 23, 2025
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients wi...
December 22, 2025
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
November 18, 2025
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
November 14, 2025
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Post...
October 23, 2025
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
October 16, 2025
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESP...
September 15, 2025
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
September 8, 2025
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
August 28, 2025
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
August 8, 2025
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
July 31, 2025
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteop...
July 28, 2025
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ES...
July 8, 2025
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentati...
June 26, 2025
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disor...
June 25, 2025
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
May 9, 2025
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopau...
April 15, 2025
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
March 28, 2025
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Ob...
March 17, 2025
Entera Bio to Participate in Upcoming Events
February 24, 2025
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for ...
February 19, 2025
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
January 27, 2025
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
November 8, 2024
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity an...
September 25, 2024
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
August 20, 2024
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
August 9, 2024